<VariationArchive VariationID="1323006" VariationName="NM_000169.3(GLA):c.1042dup (p.Ala348fs)" VariationType="Duplication" Accession="VCV001323006" Version="4" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-07-15" DateCreated="2021-11-29" MostRecentSubmission="2024-02-14">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1313296" VariationID="1323006">
      <GeneList>
        <Gene Symbol="GLA" FullName="galactosidase alpha" GeneID="2717" HGNC_ID="HGNC:4296" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>Xq22.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="101397803" stop="101407925" display_start="101397803" display_stop="101407925" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="100652778" stop="100663000" display_start="100652778" display_stop="100663000" Strand="-" />
          </Location>
          <OMIM>300644</OMIM>
          <Haploinsufficiency last_evaluated="2021-03-24" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=GLA">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-03-24" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=GLA">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
        <Gene Symbol="RPL36A-HNRNPH2" FullName="RPL36A-HNRNPH2 readthrough" GeneID="100529097" HGNC_ID="HGNC:48349" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>Xq22.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="101391011" stop="101414133" display_start="101391011" display_stop="101414133" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="100645877" stop="100669127" display_start="100645877" display_stop="100669127" Strand="+" />
          </Location>
        </Gene>
      </GeneList>
      <Name>NM_000169.3(GLA):c.1042dup (p.Ala348fs)</Name>
      <CanonicalSPDI>NC_000023.11:101398056:C:CC</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>Xq22.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="101398056" stop="101398057" display_start="101398056" display_stop="101398057" variantLength="1" positionVCF="101398056" referenceAlleleVCF="G" alternateAlleleVCF="GC" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="100653044" stop="100653045" display_start="100653044" display_stop="100653045" variantLength="1" positionVCF="100653044" referenceAlleleVCF="G" alternateAlleleVCF="GC" />
      </Location>
      <ProteinChange>A348fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.10" sequenceAccession="NC_000023" sequenceVersion="10" change="g.100653045dup" Assembly="GRCh37">
            <Expression>NC_000023.10:g.100653045dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.11" sequenceAccession="NC_000023" sequenceVersion="11" change="g.101398057dup" Assembly="GRCh38">
            <Expression>NC_000023.11:g.101398057dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007119.1" sequenceAccession="NG_007119" sequenceVersion="1" change="g.14907dup">
            <Expression>NG_007119.1:g.14907dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000169.3" sequenceAccession="NM_000169" sequenceVersion="3" change="c.1042dup" MANESelect="true">
            <Expression>NM_000169.3:c.1042dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000160.1" sequenceAccession="NP_000160" sequenceVersion="1" change="p.Ala348fs">
            <Expression>NP_000160.1:p.Ala348fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="non-coding">
          <NucleotideExpression sequenceAccessionVersion="NR_164783.1" sequenceAccession="NR_164783" sequenceVersion="1" change="n.1121dup">
            <Expression>NR_164783.1:n.1121dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001619" Type="non-coding transcript variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001199973.2" sequenceAccession="NM_001199973" sequenceVersion="2" change="c.300+2600dup">
            <Expression>NM_001199973.2:c.300+2600dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001199974.2" sequenceAccession="NM_001199974" sequenceVersion="2" change="c.177+6235dup">
            <Expression>NM_001199974.2:c.177+6235dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_672" sequenceAccession="LRG_672">
            <Expression>LRG_672:g.14907dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_672t1" sequenceAccession="LRG_672t1">
            <Expression>LRG_672t1:c.1042dup</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2147471207" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000169.3(GLA):c.1042dup (p.Ala348fs) AND not provided" Accession="RCV001783370" Version="4">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-05-04" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000169.3(GLA):c.1042dup (p.Ala348fs) AND Fabry disease" Accession="RCV003509693" Version="1">
        <ClassifiedConditionList TraitSetID="3012">
          <ClassifiedCondition DB="MedGen" ID="C0002986">Fabry disease</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-11-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-11-01" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2021-11-29" MostRecentSubmission="2024-02-14">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">12175777</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">12428061</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">28768754</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">31392112</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">33437642</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="3012" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1790" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Fabry's disease</ElementValue>
                <XRef ID="Fabry+Disease/2690" DB="Genetic Alliance" />
                <XRef ID="16652001" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ceramide trihexosidosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Fabry disease</ElementValue>
                <XRef ID="MONDO:0010526" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Angiokeratoma, diffuse</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Anderson-Fabry disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary dystopic lipidosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpha-galactosidase A deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GLA deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Angiokeratoma corporis diffusum</ElementValue>
                <XRef ID="HP:0001071" DB="Human Phenotype Ontology" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ceramide trihexosidase deficiency</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="disease mechanism">Fabry disease is due to inactivating mutations in the X-linked GLA gene resulting in deficiency of the enzyme Alpha Galactosidase-A.</Attribute>
                <XRef ID="GTR000500007" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000556520" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000591289" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528276" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507480" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520414" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551442" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512526" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520063" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000514924" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000568367" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000596367" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558532" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552214" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000505068" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507942" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528536" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522527" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528516" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528500" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528528" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000325415" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000556501" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000246735" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520447" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000260631" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6400" />
                <XRef ID="6400" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Fabry disease is the most common of the lysosomal storage disorders and results from deficient activity of the enzyme alpha-galactosidase A (α-Gal A), leading to progressive lysosomal deposition of globotriaosylceramide and its derivatives in cells throughout the body. The classic form, occurring in males with less than 1% α-Gal A enzyme activity, usually has its onset in childhood or adolescence with periodic crises of severe pain in the extremities (acroparesthesia), the appearance of vascular cutaneous lesions (angiokeratomas), sweating abnormalities (anhidrosis, hypohidrosis, and rarely hyperhidrosis), characteristic corneal and lenticular opacities, and proteinuria. Gradual deterioration of renal function to end-stage renal disease (ESRD) usually occurs in men in the third to fifth decade. In middle age, most males successfully treated for ESRD develop cardiac and/or cerebrovascular disease, a major cause of morbidity and mortality. Heterozygous females typically have milder symptoms at a later age of onset than males. Rarely, females may be relatively asymptomatic throughout a normal life span or may have symptoms as severe as those observed in males with the classic phenotype. In contrast, late-onset forms occur in males with greater than 1% α-Gal A activity. Clinical manifestations include cardiac disease, which usually presents in the sixth to eighth decade with left ventricular hypertrophy, cardiomyopathy, arrhythmia, and proteinuria; renal failure, associated with ESRD but without the skin lesions or pain; or cerebrovascular disease presenting as stroke or transient ischemic attack.</Attribute>
                <XRef ID="NBK1292" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301469</ID>
                <ID Source="BookShelf">NBK1292</ID>
              </Citation>
              <Citation Type="general">
                <ID Source="pmc">3009617</ID>
              </Citation>
              <Citation Type="general" Abbrev="HFSA, 2010">
                <ID Source="PubMed">20610207</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2002">
                <ID Source="PubMed">12735292</ID>
              </Citation>
              <Citation Type="general" Abbrev="Eng et al., 2006">
                <ID Source="PubMed">16980809</ID>
              </Citation>
              <Citation Type="general" Abbrev="Salviati et al, 2010">
                <ID Source="pmc">2869001</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="EuroGentest, 2011">
                <ID Source="PubMed">21934708</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="general" Abbrev="AHA/ASA, 2014">
                <ID Source="PubMed">25355838</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2013">
                <ID Source="PubMed">23860966</ID>
              </Citation>
              <Citation Type="general" Abbrev="ESC, 2014">
                <ID Source="PubMed">25173338</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="AHA/ACC/HFSA, 2022">
                <ID Source="PubMed">35378257</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACC/AHA/HFSA, 2017">
                <ID Source="PubMed">28461259</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Fabry.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased a-galactosidase A, Fabry Disease, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Fabry-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Alpha-galactosidase A (alpha- gal A) Deficiency, 2022</CitationText>
              </Citation>
              <XRef ID="324" DB="Orphanet" />
              <XRef ID="C0002986" DB="MedGen" />
              <XRef ID="MONDO:0010526" DB="MONDO" />
              <XRef Type="MIM" ID="301500" DB="OMIM" />
              <XRef Type="primary" ID="HP:0001071" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="3964483" SubmissionDate="2024-01-26" DateLastUpdated="2024-02-04" DateCreated="2021-11-29">
        <ClinVarSubmissionID localKey="a90547b644b321f360acdca068fa1599909bc8cf479647979cddfbbc2dd48801|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002024297" DateUpdated="2024-02-04" DateCreated="2021-11-29" Type="SCV" Version="3" SubmitterName="Revvity Omics, Revvity" OrgID="167595" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-05-04">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000169.2:c.1042dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10694847</SubmissionName>
          <SubmissionName>SUB12926214</SubmissionName>
          <SubmissionName>SUB14173319</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7984508" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2024-02-14">
        <ClinVarSubmissionID localKey="4976135|MedGen:C0002986" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004299623" DateUpdated="2024-02-14" DateCreated="2024-02-14" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-11-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">12175777</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">33437642</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12428061</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">28768754</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">31392112</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Ala348Glyfs*27) in the GLA gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 82 amino acid(s) of the GLA protein. This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individuals with Fabry disease (PMID: 12175777, 33437642). ClinVar contains an entry for this variant (Variation ID: 1323006). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. This variant disrupts a region of the GLA protein in which other variant(s) (p.Pro409Ser) have been determined to be pathogenic (PMID: 12428061, 28768754, 31392112; Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000023.10:g.100653044_100653045insC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0002986" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14200283</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="3964483" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7984508" TraitType="Disease" MappingType="XRef" MappingValue="C0002986" MappingRef="MedGen">
        <MedGen CUI="C0002986" Name="Fabry disease" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

